Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 1, 2011, Pages 169-173

  Reichenberger, Frank ^a   Mainwood, Ann ^a   Morrell, Nicholas W ^a   Parameshwar, Jayan ^a   Pepke Zaba, Joanna ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Epoprostenol; High dose inhaled iloprost; Long term treatment; Pulmonary hypertension

Indexed keywords

BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LONG TERM CARE; LUNG ARTERY PRESSURE; MALE; OPEN STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TOTAL LUNG CAPACITY; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 79251596905     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.06.004     Document Type: Article

References (36)

1. Badesch D.B., Abman S.H., Ahearn G.S., Barst R.J., McCrory D.C., Simonneau G., et al. American college of chest physicians. Medical therapy for pulmonary arterial hypertension: aCCP evidence-based clinical practice guidelines. Chest 2004, 126:35S-62S.
2. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334:296-302. for The Primary Pulmonary Hypertension Study Group.
3. Badesch D.B., Tapson V.F., McGoon M.D., Brundage B.H., Rubin L.J., Wigley F.M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425-434.
4. Higenbottam T., Wheeldon D., Wells F., Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984, 8385:1046-1047.
5. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002, 40:780-788.
6. Higenbottam T., Butt A.Y., McMahon A., Westerbeck R., Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998, 80:151-155.
7. Graham D.R., Keldermans M.M., Klemm L.W., Semenza N.J., Shafer M.L. Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. Am J Med 1991, 91:95S-100S.
8. Fishman A.P. Epoprostenol (prostacyclin) and pulmonary hypertension. Ann Intern Med 2000, 132:500-502.
9. Hoeper M.M., Gall H., Seyfarth H.J., Halank M., Ghofrani H.A., Winkler J., et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009, 34:132-137.
10. Olschewski H., Ghofrani A., Schmehl T., Winkler J., Wilkens H., Hoeper M.M., et al. Inhaled iloprost to treat severe pulmonary hypertension. Ann Intern Med 2000, 132:435-443.
11. Hoeper M.M., Schwarze M., Ehlerding S., Adler-Schuermeyer A., Spiekerkoetter E., Niedermeyer J., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000, 342:1866-1870.
12. Olschewski H., Ghofrani H.A., Walmrath D., Schermuly R., Temmesfeld-Wollbruck B., Grimminger F., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999, 160:600-607.
13. Olschewski H., Simonneau G., Galie N., Higenbottam T., Naeije R., Rubin L.J., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
14. Wilkins M.R., Paul G.A., Strange J.W., Tunariu N., Gin-Sing W., Banya W.A., et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005, 171:1292-1297.
15. McLaughlin V.V., Presberg K.W., Doyle R.L., Abman S.H., McCrory D.C., Fortin T., et al. American college of chest physicians. Prognosis of pulmonary arterial hypertension: aCCP evidence-based clinical practice guidelines. Chest 2004, 126:78S-92S.
16. Gessler T., Schmehl T., Hoeper M.M., Rose F., Ghofrani H.A., Olschewski H., et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J 2001, 17:14-19.
17. Reichenberger F., Mainwood A., Doughty N., Fineberg A., Morrell N.W., Pepke-Zaba J. Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respir Med 2007, 101:217-222.
18. Goodman T. Towards evidence - based medical statistics. Ann Intern Med 1999, 130:995-1013.
19. Reichenberger F., Pepke-Zaba J., McNeil K., Parameshwar J., Shapiro L.M. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax 2003, 58:797-800.
20. Shapiro S.M., Oudiz R.J., Cao T., Romano M.A., Beckmann X.J., Georgiou D., et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997, 30:343-349.
21. Oudiz R.J., Farber H.W. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J 2009, 157:625-635.
22. Gomberg-Maitland M., Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008, 31:891-901.
23. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergowsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
24. Miyamoto S., Nagaya N., Atoh T., Kyotani S., Sakamaki F., Fujita M., et al. Clinical correlates and prognostic significance of six minute walk test in patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2000, 161:487-492.
25. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
26. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., et al. Sildenafil use in pulmonary arterial hypertension (SUPER) study group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
27. Galie N., Manes A., Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 2001, 22:529-537.
28. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436.
29. Hoeper M.M., Markevych I., Spiekerkoetter E., Welte T., Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005, 26:858-863.
30. Wilkens H., Guth A., Konig J., Forestier N., Cremers B., Hennen B., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001, 104:1218-1222.
31. Ghofrani H.A., Wiedemann R., Rose F., Olschewski H., Schermuly R.T., Weissmann N., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002, 136:515-522.
32. Ghofrani H.A., Rose F., Schermuly R.T., Olschewski H., Wiedemann R., Kreckel A., et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003, 42:158-164.
33. Hoeper M.M., Taha N., Bekjarova A., Gatzke R., Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostaglandin analogues. Eur Respir J 2003, 22:330-334.
34. Humbert M., Barst R.J., Robbins I.M., Channick R.N., Galie N., Boonstra A., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004, 24:353-359.
35. McLaughlin V.V., Oudiz R.J., Frost A., Tapson V.F., Murali S., Channick R.N., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:1257-1263.
36. Simonneau G., Rubin L.J., Galiè N., Barst R.J., Fleming T.R., Frost A.E., et al. PACES study group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.